Non-renal excretion makes a difference:
no need for dose-adjustment when renal function declines.

TRAJENTA® is different from most of the other DPP4 inhibitors (DPP4i) because it is primarily excreted via a non-kidney route. That makes TRAJENTA® simple to use:1

Click on the DPP4i below to reveal the share of renal excretion in %

Trajenta 5%
  • No requirement for additional drug-related renal function monitoring1
  • No dose adjustment required in patients with renal impairment1

This means that when used appropriately, TRAJENTA® provides a simple way for patients to stay on a licensed dose of DPP4i, even as renal function declines.1-4 Real-world evidence has shown that a high proportion of patients being treated with DPP4i are at risk of being on unlicensed doses.2-4 Indeed, DPP4i doses are not always adjusted in accordance with guidelines or recommendations as renal function declines.2-4

TRAJENTA®: The only approved DPP4i that does not require dose reduction based on renal function.1-5

Required DPP4i dose with declining renal function, as measured by CrCl1-5


real-world studies dosing


Different studies have shown that a significant proportion of renally impaired patients receive an unlicensed DPP4i dose1-3

of DPP4i patients (excluding patients treated with TRAJENTA®) with moderate to severe chronic kidney disease were on an unlicensed dose according to claims data (n=380)*1

moderate RI, severe RI and end-stage renal disease patients received unlicensed sitagliptin doses according to General Electric Centricity data (n=1,476)**2

*The objective of this retrospective database study was to describe real world patterns of DPP4i use and to assess concordance with PI recommended dosing among patients with T2D and moderate to severe chronic kidney disease (CKD) (Stage 3b-5; indicated by eGFR value <45 mL/min/1.73m²) treated with sitagliptin, saxagliptin, or linagliptin. The study used Quintiles’ electronic medical records (Q-EMR) linked to administrative claims from Truven’s MarketScan database 2010-2014 in the US; 492 DPP4i patients with moderate to severe CKD were identified (323 on sitagliptin, 57 on saxagliptin, 112 on linagliptin).
**Patients were classified as moderate (eGFR 30-59 mL/min/1.73m²), severe (eGFR 15-29 mL/min/1.73m²), end-stage (eGFR <15 mL/min/1.73m²). Retrospective database analysis using GE Centricity Outpatient Electronic Medical Records. Patients aged 18 years with evidence of type 2 diabetes between January 1, 2000 and June 30, 2009, and 12 months of data after identification were selected. Patients included in the study sample were required to have evidence of renal impairment, as indicated by an eGFR calculated using Scr tests (n=1,476). All treatment changes were evaluated in the 30 days after the first eGFR calculation indicating renal impairment.


Hear what experts are saying about TRAJENTA® simplicity in dosing